MedPath

Amgen's Rocatinlimab and Uplizna Phase 3 Data Impact Stock

• Amgen's stock experienced a 3% dip following the release of Phase 3 trial data for rocatinlimab and Uplizna, impacting investor confidence. • The MITIGATE Phase 3 trial assessed the efficacy and safety profiles of rocatinlimab and Uplizna, providing critical insights into their clinical applications. • Detailed findings from the Phase 3 trials were presented online, offering a comprehensive overview of the drugs' performance and potential benefits.

Amgen (NASDAQ: AMGN) witnessed a 3% decline in its stock value during post-market trading after the company released Phase 3 trial data for two of its key drugs, rocatinlimab and Uplizna. The data, presented online, detailed the outcomes of the MITIGATE Phase 3 trial, which evaluated the efficacy and safety of these drugs.
The MITIGATE trial aimed to provide a comprehensive assessment of rocatinlimab and Uplizna, offering insights into their potential clinical applications and benefits. The findings are expected to influence treatment strategies and patient outcomes in relevant therapeutic areas. Investors and analysts are closely scrutinizing the data to understand the implications for Amgen's future performance and market positioning.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

AbbVie Reassesses Emraclidine's Future After Phase II Schizophrenia Trial Failures

AbbVie's emraclidine failed to meet primary endpoints in Phase II trials for schizophrenia, leading to a $3.5 billion impairment charge and a reevaluation of its development path.
The company is now focusing on emraclidine as an adjunctive treatment for schizophrenia and as a monotherapy for psychosis related to Alzheimer's and Parkinson's diseases.

Galectin Therapeutics' Belapectin Fails to Meet Primary Endpoint in MASH Cirrhosis Trial

Galectin Therapeutics' NAVIGATE trial of belapectin in MASH cirrhosis patients with portal hypertension did not meet its primary endpoint of preventing varices.
While belapectin reduced varices incidence in the intent-to-treat population, the difference was not statistically significant compared to placebo.

Repare Therapeutics' Shares Plunge After Mixed Phase 1 Results for Lunresertib and Camonsertib Combination

Repare Therapeutics' shares fell 38% following Phase 1 results of lunresertib and camonsertib in endometrial and platinum-resistant ovarian cancers.
The combination therapy showed a 25.9% overall response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer patients.

Eyenovia's Stock Plummets After Phase III Myopia Trial Fails to Meet Primary Endpoint

Eyenovia's stock price plummeted after its Phase III CHAPERONE study, evaluating a drug-device combination for pediatric progressive myopia, failed to meet its primary endpoint.
The CHAPERONE trial assessed low-dose atropine delivered via the Optejet platform but did not demonstrate a statistically significant difference in myopia progression compared to the comparator arm.

Moleculin Biotech's Annamycin Shows Promise in R/R AML, Phase 3 Trial Launching in Q1 2025

Moleculin Biotech is set to begin dosing in its Phase 3 MIRACLE trial of Annamycin plus cytarabine for relapsed/refractory AML in Q1 2025, designed for potential accelerated approval.
Preliminary data from the MB-106 Phase 1B/2 AML trial shows the median durability of complete response composite (CRc) continues to increase, now exceeding eight months.

Pharma Giants Report Q3 Earnings: Merck, Pfizer, AbbVie, and Novartis Lead with Key Drug Updates

Merck's Keytruda sales surged 17% due to strong uptake in earlier-stage indications, while a new Phase III trial for a personalized mRNA cancer vaccine in NSCLC was initiated.
Pfizer's Q3 revenues increased by 32%, driven by non-COVID products and Seagen acquisitions, leading to raised 2024 earnings and revenue expectations.

Amgen's Q3 2024 Revenue Jumps 23% Fueled by Rare Disease Portfolio

Amgen reported an impressive 23% revenue increase in Q3 2024, reaching $8.5 billion, driven by strong product sales, particularly in its rare disease portfolio.
The rare disease portfolio, boosted by the Horizon Therapeutics acquisition, saw a 21% year-over-year growth, with key drugs like Tepezza, Krystexxa, and Uplizna contributing significantly.

Tyra Biosciences' FGFR3 Inhibitor TYRA-300 Shows Promise in Urothelial Cancer

Tyra Biosciences' TYRA-300 demonstrated encouraging phase I/II data in metastatic urothelial cancer, offering a potential new treatment option.
The Surf301 trial results were described as 'fantastic' by analysts, highlighting the drug's potential clinical impact.

Amgen's Uplizna Shows Promise in Myasthenia Gravis Trial, Rocatinlimab Data Disappoints

Amgen's Uplizna met its primary endpoint in a Phase 3 trial for generalized myasthenia gravis (gMG), demonstrating statistically significant improvement in daily living activities.
The MINT trial for Uplizna included both AChR+ and MuSK+ patients, showing clinically meaningful changes in MG-ADL and QMG scores compared to placebo.

Reference News

[1]
Amgen stock slips 3% following Phase 3 data for rocatinlimab, Uplizna - Seeking Alpha
seekingalpha.com · Sep 25, 2024

Amgen shares fell 3% post-market after reporting Phase 3 data for Uplizna and rocatinlimab.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy